Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Baxdrostat SCHEMBL30768266 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| Baxdrostat SCHEMBL14799507 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| Baxdrostat SCHEMBL14799753 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| Baxdrostat SCHEMBL30768271 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL31180372 | 0.96 | CYP11B2 (0.93) | CYP11B2CYP11B1 | |
| SCHEMBL14799875 | 0.95 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL14799650 | 0.95 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL14799849 | 0.95 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL31180329 | 0.94 | CYP11B2 (0.88) | CYP11B2CYP11B1 | |
| SCHEMBL31180342 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758388-B1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-02-21 | — | — | EP | claimed |
| US-9353081-B2 | Bicyclic dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | claimed |
| EP-2758388-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | claimed |
| CN-103827101-A | New bicyclic dihydroquinoline-2-one derivatives | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | claimed |
| US-20130079365-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-28 | — | — | US | claimed |
| WO-2013041591-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | claimed |
| US-20260041679-A1 | METHOD OF TREATING HYPERTENSION WITH THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT | CINCOR PHARMA INC (US) | 2026-02-12 | — | — | US | disclosed |
| CN-117545482-A | Methods of using aldosterone synthase inhibitors | 新科药业公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2022272300-A1 | METHODS OF USING ALDOSTERONE SYNTHASE INHIBITORS | CINCOR PHARMA, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-2758388-B1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-2758388-B1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-9353081-B2 | Bicyclic dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353081-B2 | Bicyclic dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2758388-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| CN-103827101-A | New bicyclic dihydroquinoline-2-one derivatives | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | disclosed |
| WO-2013041591-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079365-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013041591-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079365-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079365-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079365-A1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | REN, MC2R, C1S | CYP11B2 5/4885CYP11B1 8/4885 |
| US-20260041679-A1 | METHOD OF TREATING HYPERTENSION WITH THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT | VASP, HSD11B1, HSD3B1 | CYP11B2 30/4885CYP11B1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.